Unknown

Dataset Information

0

Biomarkers for Immunotherapy in Poorly Differentiated Sinonasal Tumors


ABSTRACT: The sinonasal cavities harbor a wide variety of rare cancer types. Histopathological classification can be challenging, especially for poorly differentiated tumors. Despite advances in surgery and radio-chemotherapy, the 5-year survival rate is still very low. Thus, there is an unmet clinical need for new therapeutic options. We retrospectively evaluated poorly differentiated tumors of 9 different histological subtypes from 69 patients who had received conventional treatments for the presence of CD8+ tumor-infiltrating lymphocytes (TILs), as well as the expression of PD-L1 and microsatellite instability (MSI) markers MLH1, MSH2, MSH6 and PMS2, as biomarkers for immunotherapy. CD8+ TILs were present in 23/69 (33%) cases, PD-L1 expression was observed in 23/69 (33%), and markers for MSI positivity in 5/69 (7%) cases. CD8+ TILs correlated with PD-L1 positivity, while both were mutually exclusive with MSI markers. None of the biomarkers were associated with clinical features as age, gender or tumor stage. Cases with CD8+ TILs and PD-L1 positivity showed a tendency toward worse disease-specific survival. Immune checkpoint inhibitors are emerging as new options for treatment of many tumor types. Our results indicate that also a substantial subset of patients with poorly differentiated sinonasal tumors may be a candidate to be treated with this promising new therapy.

SUBMITTER: Villanueva-Fernandez E 

PROVIDER: S-EPMC9496628 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC10844182 | biostudies-literature
| S-EPMC8507885 | biostudies-literature
| S-EPMC5639875 | biostudies-literature
| S-EPMC8633219 | biostudies-literature
| S-EPMC8373679 | biostudies-literature
| S-EPMC2912221 | biostudies-literature
| S-EPMC8870162 | biostudies-literature
2022-10-28 | GSE173107 | GEO
| S-EPMC2077885 | biostudies-other
| S-EPMC7017229 | biostudies-literature